Journal: Journal of integrative neuroscience

Article Title: Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway.

doi: 10.31083/j.jin2308142

Figure Lengend Snippet: Fig. 1. Fingolimod effectively reduces cerebral infarction volume, alleviates cerebral edema, and improves neurological function in MCAO/R rats. (A) On the first day post-MCAO/R procedure, TTC staining images were captured, wherein the infarcted regions of

Article Snippet: Fingolimod (Cat #HY-11063, MedChemExpress, Monmouth Junction, NJ, USA) was prepared in dimethylsulfoxide (DMSO, D8371, Beijing Solebao Technology Co., Ltd., Beijing, China) and diluted in a 0.9% NaCl saline solution to final concentrations (0.5, 1.0, and 2.0 mg/kg).

Techniques: Staining

Journal: Journal of integrative neuroscience

Article Title: Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway.

doi: 10.31083/j.jin2308142

Figure Lengend Snippet: Fig. 2. Fingolimod inhibits inflammation in rats after MCAO/R. (A) Enzyme-Linked Immunosorbent Assay (ELISA) was employed to measure the serum concentrations of interleukin-1 beta (IL-1β) in rats, with data expressed as the mean ± SD and analyzed utilizing

Article Snippet: Fingolimod (Cat #HY-11063, MedChemExpress, Monmouth Junction, NJ, USA) was prepared in dimethylsulfoxide (DMSO, D8371, Beijing Solebao Technology Co., Ltd., Beijing, China) and diluted in a 0.9% NaCl saline solution to final concentrations (0.5, 1.0, and 2.0 mg/kg).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of integrative neuroscience

Article Title: Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway.

doi: 10.31083/j.jin2308142

Figure Lengend Snippet: Fig. 3. Fingolimod down-regulates the expression of HMGB1 in MCAO/R rats. (A) The expression levels of HMGB1 within the hippocampal region of these rats were measured using the technique of western blot analysis, with the assessment being conducted day 1

Article Snippet: Fingolimod (Cat #HY-11063, MedChemExpress, Monmouth Junction, NJ, USA) was prepared in dimethylsulfoxide (DMSO, D8371, Beijing Solebao Technology Co., Ltd., Beijing, China) and diluted in a 0.9% NaCl saline solution to final concentrations (0.5, 1.0, and 2.0 mg/kg).

Techniques: Expressing, Western Blot

Journal: Journal of integrative neuroscience

Article Title: Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway.

doi: 10.31083/j.jin2308142

Figure Lengend Snippet: Fig. 4. Fingolimod inhibits TLR4 expression in MCAO/R rats. (A) The expression of TLR4 in the hippocampus of rats was detected

Article Snippet: Fingolimod (Cat #HY-11063, MedChemExpress, Monmouth Junction, NJ, USA) was prepared in dimethylsulfoxide (DMSO, D8371, Beijing Solebao Technology Co., Ltd., Beijing, China) and diluted in a 0.9% NaCl saline solution to final concentrations (0.5, 1.0, and 2.0 mg/kg).

Techniques: Expressing

Journal: Journal of integrative neuroscience

Article Title: Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway.

doi: 10.31083/j.jin2308142

Figure Lengend Snippet: Fig. 5. Fingolimod treatment reduces NF-κBp65 expression in MCAO/R rats. (A) The expression of NF-κBp65 in the hippocampus of rats was detected using western blot analysis on day 1 after MCAO/R. (B) Quantification analysis of NF-κBp65 via western blot (Data

Article Snippet: Fingolimod (Cat #HY-11063, MedChemExpress, Monmouth Junction, NJ, USA) was prepared in dimethylsulfoxide (DMSO, D8371, Beijing Solebao Technology Co., Ltd., Beijing, China) and diluted in a 0.9% NaCl saline solution to final concentrations (0.5, 1.0, and 2.0 mg/kg).

Techniques: Expressing, Western Blot

Journal: Cell Reports Medicine

Article Title: Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice

doi: 10.1016/j.xcrm.2021.100455

Figure Lengend Snippet: Testing the therapeutic potency of MSC-IPr (A) Kaplan-Meier survival curve. Tumor implantation is shown by the blue arrow, whereas vaccination is represented by black arrows. Tumor growth assessment of Ctl mice (black), DC (green), MSCγ (blue), or MSC-IPr (red). The anti-OVA western blot represents (1) OVA protein, (2) EL4, (3) cultured E.G7, and (4) E.G7 isolated from tumor masses. (B and C) Flow cytometry assessment of immune-checkpoint expression by CD8 T cells isolated from tumor masses. (D) A pie chart representing CD8 T cells expressing immune checkpoints. (E) Kaplan-Meier survival curve of mice implanted with EL4 and vaccinated using lysate-pulsed MSC-IPr. MSC-IPr alone are in red, in combination with anti-41BB in dotted black line, anti-LAG3 in yellow, anti-CTLA4 in blue, or anti-PD-1 antibodies in orange. 4-1BB is represented by dotted blue line, anti-LAG3 is in gray, anti-CTL4 is in green, and anti-PD-1 is in purple. (F) Kaplan-Meier survival curve of mice implanted as in (E) and receiving no treatment (black), anti-PD-1/4-1BB (purple), FTY720 (green), MSC-IPr + PD-1/4-1BB (orange), or MSC-IPr + PD-1/4-1BB and FTY720 (blue). (G) Representative live in vivo imaging of mice implanted with luciferase-expressing Ctl MSCs versus MSC-IPr. (H) Assessment of the signal decay for the experiment shown in (G). (I and J) Experimental design and Kaplan-Meier survival curve of allogeneic vaccination using DCs (green), DCs + αPD-1 (dotted green), MSC-IPr (red), and MSC-IPr + αPD-1 (dotted red). Ctl mice are shown in black, whereas αPD-1 is in dotted black. For (A) to (F) and (J), n = 10/group; for (G) and (H), n = 6/group, with ∗∗p < 0.01 and ∗∗∗p < 0.001. The log rank statistical test was used for the Kaplan-Meir survival curves. Error bars represent SD. See also .

Article Snippet: FTY720 , Tocris , N/A.

Techniques: Tumor Implantation, Western Blot, Cell Culture, Isolation, Flow Cytometry, Expressing, In Vivo Imaging, Luciferase

Journal: Cell Reports Medicine

Article Title: Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice

doi: 10.1016/j.xcrm.2021.100455

Figure Lengend Snippet:

Article Snippet: FTY720 , Tocris , N/A.

Techniques: Recombinant, Liposomes, Control, Flow Cytometry, Live Cell Imaging, Enzyme-linked Immunosorbent Assay, Selection, Construct, Software

Journal: Scientific reports

Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

doi: 10.1038/s41598-023-46011-4

Figure Lengend Snippet: Figure 2. S1P and FTY720P induce lipid accumulation in HepG2 cells. Lipid accumulation in the presence of (a) Sphk1 inhibitor PF543; (b) blockers of all S1PRs. Values are means ± SEM. N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05; c) various concentrations of the S1P analog FTY720P. Values are means ± SEM; N = 3. *Significantly different from the control at P < 0.05.

Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

Techniques: Control

Journal: Scientific reports

Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

doi: 10.1038/s41598-023-46011-4

Figure Lengend Snippet: Figure 3. Effect of FTY720P on lipid accumulation in the presence of (a) S1PR1 blocker W146. (b) S1PR2 blocker JTE 013. (c) S1PR4 blocker CYM50358. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

Techniques:

Journal: Scientific reports

Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

doi: 10.1038/s41598-023-46011-4

Figure Lengend Snippet: Figure 4. S1PR3 and Gq mediate the FTY720P effect on lipid accumulation. (a) Effect of FTY720P on lipid accumulation in the presence of S1PR3 blocker CAY10444. (b) Effect of FTY720P on lipid accumulation in the presence of the Gq inhibitor YM254890. (c) Protein expression of S1PR3. The blot is representative of an experiment repeated 3 times. Values were normalized to GAPDH and reported as arbitrary densitometry units. All values are means ± SEM; N = 3. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

Techniques: Expressing

Journal: Scientific reports

Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

doi: 10.1038/s41598-023-46011-4

Figure Lengend Snippet: Figure 5. Effect of FTY720P on lipid accumulation in the presence of (a) the PI3K inhibitor wortmannin. (b) the mTOR inhibitor rapamycin. All values are means ± SEM; N = 4. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

Techniques:

Journal: Scientific reports

Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

doi: 10.1038/s41598-023-46011-4

Figure Lengend Snippet: Figure 6. Effect of FTY720P on lipid accumulation in the presence of (a) the SREBP inhibitor fatostatin. (b) The PPARγ inhibitor GW9662. Values are means ± SEM; N = 5. Bars not sharing a common letter are considered significantly different from each other at P < 0.05.

Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

Techniques:

Journal: Scientific reports

Article Title: Effect of FTY720P on lipid accumulation in HEPG2 cells.

doi: 10.1038/s41598-023-46011-4

Figure Lengend Snippet: Figure 13. The signaling pathway activated by FTY720P.

Article Snippet: FTY720P (Cat # sc-205332A), rosiglitazone (Cat # sc-202795), anti-SREBP1 (Cat# sc-365513, Lot#B1821), anti-p-mTOR (Cat# sc-293132, Lot#K2717), anti-mTOR (Cat# sc-8319, Lot#K2415), anti-GAPDH (Cat# sc-47724, Lot# H0917) mouse primary antibodies as well as anti-mouse horse radish peroxidase (HRP) conjugated secondary antibodies (Cat# sc-2005, Lot# C2011) were purchased all from Santa Cruz Biotechnology, CA, USA.

Techniques:

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: (A) The number distribution of coencapsulated FTY720 and NOB NPs was prepared by the emulsification method using PLGA. (B) The morphology of the FTY720-NOB-PLGA NPs with a field of view of 30K.

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Emulsification

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: (A) FTIR spectra of the (a) FTY720, (b) NOB, (c) PLGA, and (d) FTY720-NOB-PLGA NPs with wave numbers from 500 to 4000 cm –1 . The FTY720-NOB-PLGA NPs underwent drug release at 1× PBST and 37 °C. Concentrations of FTY720 and NOB were determined at wavelengths of 200 and 330 nm and expressed as (B) grams of cumulative drug and (C) percent of total cumulative drug.

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques:

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: (A) Schematic diagram illustrating the design of the animal model. (B) Evaluation of IL-6 and TNF-α secretion in bronchoalveolar lavage fluid (BALF) from LPS-induced lung injury mice ( n = 3 per group) after 24 h of treatment with PBS, NOB-PLGA NPs, and FTY720-NOB-PLGA NPs using an ELISA kit. (C) Histopathological examination of lung tissues in mice ( n = 3 per group) with LPS-induced lung injury treated with PBS, NOB-PLGA NPs, and FTY720-NOB-PLGA NPs at 24 h, displayed at an original magnification of 100×. (D) Panoramic images of NF-κB obtained through the TissueFAXs platform and quantification of NF-κB expression percentage in the entire lung section (*** p < 0.001, ** p < 0.01, and * p < 0.05).

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Animal Model, Enzyme-linked Immunosorbent Assay, Expressing

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: (A) Schematic diagram of the animal model examining the endurance of FTY720-NOB-PLGA NPs’ efficacy over a 48 h period. (B) Assessment of IL-6 and TNF-α secretion in bronchoalveolar lavage fluid (BALF) from LPS-induced lung injury mice ( n = 3 per group) 48 h post-treatment with PBS, NOB-PLGA NPs, and FTY720-NOB-PLGA NPs using an ELISA kit. (C) Lung pathology evaluation in mice ( n = 3 per group) with LPS-induced lung injury treated with different drugs at 48 h, displayed at an original magnification of 100×. (D) Panoramic images of NF-κB obtained through the TissueFAXs platform, along with quantification of NF-κB expression percentage in the entire lung section (*** p < 0.001, ** p < 0.01, and * p < 0.05).

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Animal Model, Enzyme-linked Immunosorbent Assay, Expressing

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: (A) Schematic illustration of FTY720-NOB-PLGA NPs inhalation for 30 min daily over three consecutive days, followed by sacrifice at 96 h. (B) Comparison of the impact of different treatments (PBS and FTY720-NOB-PLGA NPs; 30 min/day for 3 days) on IL-6 and TNF-α secretion in BALF using an ELISA kit. (C) Lung pathology assessment in mice ( n = 3 per group) with LPS-induced lung injury treated with different drugs for three consecutive days. (D) Panoramic NF-κB images obtained through the TissueFAXs platform, and quantification of NF-κB expression percentage in the entire lung section. Mean ± SD values are presented, and p -values were determined using the Student’s t test (*** p < 0.001, ** p < 0.01, and * p < 0.05).

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Comparison, Enzyme-linked Immunosorbent Assay, Expressing

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: Histological analysis of lung tissue sections from control, LPS-induced acute lung injury, and post-treatment with FTY720-NOB-PLGA NPs. (A) Tissue sections were stained using H&E and immunohistochemical staining for MPO, CD68, and CD3. Positive cells are brown (magnification, 400×). Scale bar, 10 μm. (B) Quantification of neutrophils (MPO), macrophages (CD68), and T cells (CD3) per high-power field (HPF) derived from IHC data ( n = 3 per group). Data are presented as mean ± SD. Statistical significance was assessed using the Student’s t test (*** p < 0.001, ** p < 0.01).

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Control, Staining, Immunohistochemical staining, Derivative Assay

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: Multiplexed mIF assay of immune cell infiltration. (A) Representative images from the mIF assay on lung tissue from mice post-LPS stimulation with or without FTY720-NOB-PLGA nanoparticle inhalation treatment, showing staining for MPO (neutrophils), CD68 (macrophages), CD3 (T cells), and DAPI (nuclei). Scale bar, 100 μm. (B) The bar graph illustrates the proportion of neutrophils, macrophages, and T cells infiltrating the lungs of mice following LPS stimulation with or without FTY720-NOB-PLGA nanoparticle inhalation treatment. Data are presented as mean ± SD, calculated from four fields per mouse lung. Statistical significance was determined using the Student’s t test (*** p < 0.001).

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Staining

Journal: ACS Nano

Article Title: Enhancing Lung Recovery: Inhaled Poly(lactic- co -glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology

doi: 10.1021/acsnano.3c12532

Figure Lengend Snippet: Body weight, organ function, and respiratory rate in control group and treatment group. (A) Body weight percentage of mice in response to LPS and FTY720-NOB-PLGA NPs. The values presented are the mean ± SD. p values were obtained using the Student’s t test (*** p < 0.001). (B) Blood biochemical results of the FTY720-NOB-PLGA NPs following inhalation into mice ( n = 5). The results show mean and standard deviation of alanine aminotransferase (ALT), creatinine (CRE), total bilirubin (TBIL), and blood urea nitrogen (BUN). (C) Respiratory parameters: Mean of breathing frequency was analyzed during day 1 to day 3 through plethysmography associated with the Allay restrainer.

Article Snippet: FTY720 was purchased from TargetMol Chemicals Inc. (USA).

Techniques: Control, Standard Deviation

Journal: Journal of Leukocyte Biology

Article Title: Rapid externalization of 27-kDa heat shock protein (HSP27) and atypical cell death in neutrophils treated with the sphingolipid analog drug FTY720

doi: 10.1189/jlb.3vma1114-522rr

Figure Lengend Snippet: Figure 5. RIP1K and HSP90 are involved in neutrophil death induced by FTY720. (A and B) Flow cytometric quantification of Annexin V+PI+, Annexin V+PI2, and HSP27+ neutrophils after preincubation or not with necrostatin-1 (20 mM) or Z-IETD-FMK (20 mM) for 30 min and treatment or not with FTY720 (10 mM) for 3 h. Data are from 7 independent experiments. *P , 0.05; **P , 0.01; ***P , 0.001. (C and D) Neutrophil lysates analyzed by Western blotting for caspase-8 cleavage or MLKL phosphorylation after cell death induc- tion by FTY720. Where indicated, Q-VD-OPh (20 mM), necrostatin-1 (20 mM), DPI (20 mM), or NSA (5 mM) was added for 30 min before stimulation. GAPDH analysis was performed as loading control. The results of 1 representative experiment out of 4 are presented. (E) Flow cytometric quantification of HSP27+ neutrophils incubated for 30 min in the presence of geldanamycin (10 mM), DMAG (20 mM), or radicicol (10 mM) before treatment with FTY720 (10 mM) for 3 h. Data are from 7 independent experiments. *P , 0.05; **P , 0.01.

Article Snippet: Cells were incubated with FTY720 and FTY720 (S)-phosphate (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA) or cycloheximide (Sigma, St. Louis, MO, USA) at 3 3 10/ml for 3 h. In some cases, neutrophils were preincubated for 30 min with necrostatin-1 or Z-IETD-FMK (both from Sigma); Q-VD-OPh (R&D Systems, Minneapolis, MN, USA); NSA (Tocris, Bristol, United Kingdom); geldanamycin, 17-DMAG, and radicicol (all from InvivoGen, San Diego, CA, USA); OA (Santa Cruz Biotechnology); or DPI (Sigma).

Techniques: Western Blot, Phospho-proteomics, Control, Incubation